Literature DB >> 28743122

Utility of Transbronchial Lung Cryobiopsy in Non-Interstitial Diseases.

Olivia Sánchez-Cabral1, Dina Martínez-Mendoza, Sebastián Fernandez-Bussy, Berenice López-González, Carolina Perea-Talamantes, Rosa María Rivera-Rosales, César Luna-Rivero, José Arturo Martínez-Orozco, Luis Felipe Flores-Suárez, Patricio Santillán-Doherty, Gustavo Reyes-Terán.   

Abstract

BACKGROUND: Transbronchial lung cryobiopsy (TLCB), performed with a flexible cryoprobe, is an interventional pulmonology procedure that has proved its diagnostic value for interstitial pulmonary disease. However, it has not been explored extensively as a diagnostic tool for patients with non-interstitial lung pathology, including infectious and malignant diseases.
OBJECTIVE: To evaluate the diagnostic yield and safety of an interventional pulmonology approach that integrates TLCB and bronchoalveolar lavage (BAL) for the diagnosis of non-interstitial pulmonary disease.
METHODS: TLCB and BAL were performed under general anesthesia through the same bronchoscopic access on 103 adult patients (including immunocompromised HIV+ individuals) with clinical/radiological evidence of non-interstitial lung disease admitted to the Interventional Pulmonology Service between May 2015 and April 2016. Samples obtained were sent to pathology and microbiology laboratories for standard diagnostic analysis.
RESULTS: Samples of TLCB allowed the diagnosis of 75.7% of patients, while 39.8% were diagnosed from BAL. The global diagnostic yield from the dual sampling was 92.2%. TLCB allowed the diagnosis of 94.7% of cancer cases and 60.0% of infectious cases, while BAL samples identified 77.5% of infectious cases and 21.2% of malignant lesions. The incidence of complications was 4.9% with full recovery in all cases.
CONCLUSIONS: Simultaneous TLCB and BAL constitute a safe and useful diagnostic procedure for non-interstitial pulmonary disease, with a global diagnostic yield of 92.2%. Complementary advantages of samples obtained by each technique result in a robust diagnostic strategy for infectious and malignant disease in adults, including HIV+ individuals.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Cryobiopsy; Diagnosis; Interventional pulmonology; Lung cancer

Mesh:

Year:  2017        PMID: 28743122     DOI: 10.1159/000478786

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

1.  Novel technique to prevent central airway blood flooding during transbronchial cryobiopsy.

Authors:  Masahide Oki; Hideo Saka
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Prospective multicentre study on the safety and utility of transbronchial lung cryobiopsy with endobronchial balloon.

Authors:  Minoru Inomata; Naoyuki Kuse; Nobuyasu Awano; Mari Tone; Hanako Yoshimura; Tatsunori Jo; Jonsu Minami; Kohei Takada; Bae Yuan; Toshio Kumasaka; Hideaki Yamakawa; Shintaro Sato; Kazunori Tobino; Hidekazu Matsushima; Tamiko Takemura; Takehiro Izumo
Journal:  ERJ Open Res       Date:  2020-06-22

3.  Transbronchial lung cryobiopsy: prospective safety evaluation and 90-day mortality after a standardized examination protocol.

Authors:  Klaus Hackner; Antonia Stadler; Felix Schragel; Valerie Klamminger; Bahil Ghanim; Alexander Varga; Peter Errhalt
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 4.031

4.  GeneXpert® MTB/RIF assay with transbronchial lung cryobiopsy for Mycobacterium tuberculosis diagnosis.

Authors:  Olivia Sánchez-Cabral; Cira Santillán-Díaz; Ángel Paul Flores-Bello; Mildred Ivannia Herrera-Ortega; José Luis Sandoval-Gutiérrez; Patricio Santillán-Doherty; Dina Martínez-Mendoza
Journal:  Ann Transl Med       Date:  2020-03

5.  Transbronchial Cryobiopsy for Miliary Tuberculosis Mimicking Hypersensitivity Pneumonitis.

Authors:  Shingo Nasu; Kunimitsu Kawahara; Yuki Han; Norio Okamoto; Yoshitaka Tamura; Hidekazu Suzuki; Takayuki Shiroyama; Yumiko Samejima; Tomohiro Kanai; Yoshimi Noda; Ayako Tanaka; Naoko Morishita; Kayo Ueda; Shoji Hashimoto; Tomonori Hirashima; Takayuki Nagai
Journal:  Intern Med       Date:  2020-09-19       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.